Live
Endpoints NewsBioMarin halts Phase 2 Voxzogo dosing in certain patients over safety concernEndpoints NewsMakary pushes for IRB reforms to catch China's speedy trial startsBioPharma DiveCytomX surges on positive data for ‘masked’ ADC in colorectal cancerFierceBiotechAstellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 yearsFierceBiotechAmplifon to build vertical hearing aid player with €2.3B GN acquisitionFierceBiotechIdorsia shares sink after CEO's abrupt departureFierceBiotechDespite boosted funding, NIH still slow to award grants: analysisBioWorldOther news to note for March 16, 2026BioPharma DiveStructure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trialBioWorldPharma USA: Innovators, but architects, too; access is keyBioWorldPrecision psychiatry beyond, or before, biomarkersBioWorldBiggest gainers and losers for March 9-13, 2026
Endpoints News Mar 16, 2026

BioMarin halts Phase 2 Voxzogo dosing in certain patients over safety concern

BioMarin halts Phase 2 Voxzogo dosing in certain patients over safety concern

Original
Body unavailable. Use the original source.

Directory

59 All